Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression

Molecular Medicine

Volumn 5, Issue 1, 1999, Pages 21-34

  Chen, Lihong ^a   Lu, Wenge ^a   Agrawal, Sudhir ^b   Zhou, Wenqiang ^b   Zhang, Ruiwen ^c   Chen, Jiandong ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b HYBRIDON INC   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN MDM2; PROTEIN P53;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL LEVEL; CELL ONCOGENE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HALF LIFE TIME; HUMAN; HUMAN CELL; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INDUCTION; PROTEIN TRANSPORT;

EID: 0032975130     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03402136     Document Type: Article

References (37)

1. Levine AJ. (1997) p53, the cellular gatekeeper of growth and division. Cell 88: 323-331.
2. Hollstein M, Rice K, Greenblatt MS, et al. (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucl. Acids Res. 22: 3551-3555.
3. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83.
4. Cordon Cardo C, Latres E, Drobnjak M, et al. (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54: 794-799.
5. Lowe SW, Ruley HE, Jacks T, Housman DE. (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
6. Fakharzadeh SS, Trusko SP, George DL. (1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10: 1565-1569.
7. Finlay CA. (1993) The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell Biol. 13: 301-306.
8. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
9. Haupt Y, Maya R, Kazaz A, Oren M. (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
10. Kubbutat MHG, Jones SN, Vousden KH. (1997) Regulation of p53 stability by mdm2. Nature 387: 299-303.
11. Honda R, Tanaka H, Yasuda H. (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420: 25-27.
12. Wu X, Bayle JH, Olson D, Levine AJ. (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7: 1126-1132.
13. Barak Y, Juven T, Haffner R, Oren M. (1993) mdm2 expression is induced by wild type p53 activity. EMBO J. 12: 461-468.
14. Oca Luna RM, Wagner DS, Lozano G. (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
15. Jones SN, Roe AE, Donehower LA, Bradley A. (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208.
16. Midgley CA, Lane DP. (1997) p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15: 1179-1189.
17. Bottger A, Bottger V, Sparks A, Liu WL, Howard SF, Lane DP. (1997) Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7: 860-869.
18. Chen L, Agrawal S, Zhou W, Zhang R, Chen J. (1998) Synergistic activation of p53 by inhibition of mdm2 expression and DNA damage. Proc. Natl. Acad. Sci. U.S.A. 95: 195-200.
19. Chen J, Marechal V, Levine AJ. (1993) Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol. 13: 4107-4114.
20. Takahashi K, Sumimoto H, Suzuki K, Ono T. (1993) Protein synthesis-dependent cytoplasmic translocation of p53 protein after serum stimulation of growth-arrested MCF-7 cells. Mol. Carcinogen 8: 58-66.
21. Moll UM, LaQuaglia M, Benard J, Riou G. (1995) Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. U.S.A. 92: 4407-4411.
22. Goldman SC, Chen CY, Lansing TJ, Gilmer TM, Kastan MB. (1996) The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am. J. Pathol. 148: 1381-1385.
23. Harvey DM, Levine AJ. (1991) p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev. 5: 2375-2385.
24. Rock KL, Gramm C, Rothstein L, et al. (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771.
25. Chang YC, Lee YS, Tejima T, et al. (1998) mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 9: 79-84.
26. Landers JE, Haines DS, Strauss JF, George DL. (1994) Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9: 2745-2750.
27. Shieh SY, Ikeda M, Taya Y, Prives C. (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334.
28. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. U.S.A. 89: 7491-7495.
29. Nelson WG, Kastan MB. (1994) DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell Biol. 14: 1815-1823.
30. Shaulian E, Resnitzky D, Shifman O, et al. (1997) Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene 15: 2717-2725.
31. Moll UM, Riou G, Levine AJ. (1992) Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. U.S.A. 89: 7262-7266.
32. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G. (1996) Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell Biol. 16: 1126-1137.
33. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ. (1998) Nucleo-cytoplasmic shuttling of the hdm2-oncoprotein regulates the levels of p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17: 554-564.
34. Clarke AR, Gledhill S, Hooper ML, Bird CC, Wyllie AH. (1994) p53 dependence of early apoptotic and proliferate responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene 9: 1767-1773.
35. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849.
36. Gottlieb E, Haffner R, King A, et al. (1997) Transgenic mouse model for studying the transcriptional activity of the p53 protein: age-and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J. 16: 1381-1390.
37. Komarova EA, Chernov MV, Franks R, et al. (1997) Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J. 16: 1391-1400.